Indo US Bio-Tech
- Market cap
- ₹ 127 Cr.
- P/E
- 34.2x
- P/B
- 1.47x
- 52-week range
- 57.5 – 159
- ROE
- 15%
- ROCE
- 14%
- Dividend yield
- 0%
- Debt / equity
- 0.4
- Sector
- Agricultural Food & other Products
- Industry
- Other Agricultural Products
- Listed on
- NSE, BSE
About
Indo US Bio-Tech Limited is a specialized agriculture seed company with its own research station, marketing network and seed production bases. The Company operates through the Seed Cultivation, processing and trading segment. It is involved in crop research and development through breeding, production of seeds, processing, packing and marketing of hybrid and open-pollinated varieties of agricultural crops. Its product portfolio includes a diversified variety of agriculture seeds namely vegetable seeds, oil seeds, pulses seeds, cereals seeds, spices seeds used in cultivating all kinds of vegetables, pulses, crops like tomato, okra, brinjal, onion, bit root, cucumber, bottle gourd, groundnut, mustard, bajra, wheat, cumin, coriander, and others. It has a distribution network in the states of Gujarat, Maharashtra, Madhya Pradesh, Chhattisgarh, Rajasthan, Punjab and others. It also exports to many countries, namely the United States, New Jersey, Palestine, Cameroon, Kuwait and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Other Agricultural Products: 90 companies →Indo US Bio-Tech against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)34.2 against a typical 14.5: pricier than most peers (1st = cheapest).65th of 88
- Sales growth+7.2% against a typical +19.1% from a year earlier.41st of 68
- Profit growth−35.3% against a typical +5.4% from a year earlier.37th of 59
- Share price, 3 months+2.5% against a typical −1.7%.31st of 81
- Size₹ 127.3 Cr. market value against a typical ₹ 63 Cr. (1st = largest).29th of 85
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 30 Oct 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 12 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 29 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 21 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 14 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 14 Oct 2025 | Other business matters | Notice is hereby given pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( LODR ) that a meeting of the Board of Directors of the Company at Shorter Notice will be held on Tuesday 14th October, 2025 inter-alia, to transect the following business: 1. To consider and approve the re-appointment of M/s. Gautam N Associates as a Statutory Auditors of the Company,2. To approve Notice of Postal Ballot3. Appoint M/s. Amrish Gandhi & Associates, Practising Company Secretary scrutinizer to scrutinize the e-voting process in a fair and transparent manner for the postal ballot.4. Any other businessesThe meeting is being convened on a shorter notice as permitted under the provisions of the Companies Act, 2013. However, we confirm compliance with the SEBI LODR Regulations regarding timely intimation of the meeting to the Stock Exchange(s).This intimation is being made in compliance with the applicable provisions of the SEBI (LODR) Regulations, 2015.We request you to kindly take the above information on record. |
| 12 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 16 | 22 | 16 | 25 | 22 | 24 | 33 | 31 | 31 | 23 | 26 | 33 |
| Expenses | 13 | 18 | 15 | 21 | 17 | 18 | 29 | 25 | 27 | 19 | 23 | 29 |
| Operating Profit | 3 | 4 | 1 | 4 | 5 | 6 | 5 | 5 | 4 | 4 | 3 | 4 |
| OPM % | 16.5% | 19.1% | 6.2% | 14.9% | 23.1% | 23.5% | 13.7% | 17.8% | 13.5% | 18.2% | 12.4% | 12% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 4 | 1 | 3 | 4 | 5 | 4 | 5 | 4 | 3 | 2 | 3 |
| Tax % | 15.7% | 1.9% | 17.5% | 0.6% | 2% | −0.8% | 4.9% | 2.5% | 3.1% | 5.4% | 17.2% | 1.3% |
| Net Profit | 2 | 4 | 1 | 3 | 4 | 5 | 4 | 5 | 3 | 3 | 2 | 3 |
| EPS in Rs | 0.83 | 1.84 | 0.26 | 1.58 | 2.17 | 2.52 | 1.84 | 2.34 | 1.72 | 1.5 | 0.98 | 1.52 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 19%
- 5 Years
- 23%
- 3 Years
- 22%
- TTM
- 3%
- 10 Years
- 43%
- 5 Years
- 21%
- 3 Years
- 22%
- TTM
- −36%
- 10 Years
- —
- 5 Years
- 24%
- 3 Years
- −31%
- TTM
- —
- 10 Years
- 18%
- 5 Years
- 17%
- 3 Years
- 18%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Indo US Bio-Tech | ₹ 86.84 | ₹ 127 Cr. | 34.2x | 1.5x | 15% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Rinku Dipenbhai Jethva
- Chief Financial Officer
- Dimpy Joshi
- Compliance Officer, Company Secretary
- Jagdish Devjibhai Ajudia
- Managing Director, Executive Director
- Maltiben Jagdishbhai Ajudia
- Wholetime Director
- Priyanka Jagdishbhai Ajudia
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.